PR negative

About

Biomarker type: Protein expression

Marker: Progesterone receptor (PR)

Unit: status

Equality: =

Value: Negative

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) HSE (4) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (2) FDA (2) HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (1) HSE (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
EMA (1) ER positive, HER2-positive, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Pembrolizumab, Sacituzumab govitecan